BiomX Inc. announced a one-for-ten reverse stock split of its common stock, approved by shareholders on August 25, 2026. The Board fixed the ratio at 1-for-10 and set the effective date for September 9, 2026, when trading will resume on a split-adjusted basis on NYSE American. This action reduces authorized shares from 750 million to 150 million and outstanding shares from approximately 27.3 million to 2.7 million. Fractional shares are rounded up to whole shares at the record holder level, with no cash paid for fractions. Proportionate adjustments apply to warrants and convertible instruments. BiomX Inc. operates in the biotechnology industry, developing microbiome-based therapies.
More from Tessera Defense & Homeland Security Inc.
